



Surgical perfection. For life.

STILLE

Interim Report Q1

2026

Exceptional start to the year

- **Net sales** amounted to MSEK 179.1 (129.3), which corresponds to an organic growth of 18.6 percent (26.9 percent in constant currencies) and a total growth of 38.5 percent (46.9 percent in constant currencies).
 - **Net sales in the Surgical Instruments** business unit totaled MSEK 139.6 (98.8), an increase of 41.3 percent, or 48.9 percent in constant currencies. Organic growth was 15.2 percent, or 22.8 percent in constant currencies.
 - **Net sales in the Surgical Tables** business unit totaled MSEK 39.5 (30.5), an increase of 29.6 percent, or 40.3 percent in constant currencies.
- **The gross profit margin** was 49.1 percent (51.1).
- **EBITDA before non-recurring items** amounted to MSEK 38.5 (25.2), corresponding to an EBITDA margin of 21.5 percent (19.5).
- **EBIT before non-recurring items** amounted to MSEK 30.0 (17.9), corresponding to an EBIT margin of 16.7 percent (13.8).
- **Cash flow from operating activities** totaled MSEK 27.9 (14.1).
- **Earnings per share** amounted to SEK 2.33 (1.63).

NET SALES

179.1

MSEK

(129.3)

ORGANIC GROWTH

18.6

PERCENT

(-7.4)

EBITDA¹

38.5

MSEK

(25.2)

21.5

PERCENT

(19.5)

NET DEBT/EBITDA¹

-0.1

X

(-0.8)


1. Before non-recurring items

FINANCIAL OVERVIEW

MSEK	JAN-MAR 2026	JAN-MAR 2025	APR-MAR 2025/2026	JAN-DEC 2025
Net sales	179.1	129.3	617.4	567.6
Gross profit, %	49.1	51.1	48.7	50.7
EBITDA before non-recurring items	38.5	25.2	127.1	113.8
EBITDA before non-recurring items, %	21.5	19.5	20.6	20.0
EBITDA	38.5	25.2	120.0	106.7
EBITDA, %	21.5	19.5	19.4	18.8
EBIT before non-recurring items	30.0	17.9	92.4	80.3
EBIT before non-recurring items, %	16.7	13.8	15.0	14.2
EBIT	30.0	17.9	85.3	73.2
EBIT, %	16.7	13.8	13.8	12.9
Profit after tax	20.9	14.6	62.0	55.7
Earnings per share, SEK	2.33	1.63	6.9	6.20
Equity/assets ratio, %	67.6	72.6	67.6	67.2
Net debt/EBITDA ¹ LTM	-0.1	-0.8	-0.1	0.0


NET SALES

ROLLING 12 MONTHS, GROUP, MSEK



EBITDA¹

ROLLING 12 MONTHS, GROUP, MSEK



1. Before non-recurring items

Comments from the CEO

Exceptional start to the year with organic growth of 19% and EBIT margin expansion despite currency headwinds.

Sales increased to an all-time high of MSEK 179.1 (129.3), positively affected by the acquisition of Surgical Holdings (MSEK 25.8). Comparable figures for the quarter, excluding the effect from the acquisition, are MSEK 153.3 corresponding to organic growth of 19 percent against a low baseline from 2025. The quarter was affected by currency headwinds (MSEK 10.8) and total growth and organic growth being 47 percent and 27 percent respectively in constant currencies.

Gross margin was 49.1 percent (51.1) impacted by incorporation of Surgical Holdings and currency.

EBITDA before non-recurring items was MSEK 38.5 (25.2), corresponding to an EBITDA margin of 21.5 percent (19.5). EBIT before non-recurring items was MSEK 30,0 (17,9), corresponding to an EBIT margin of 16.7 percent and EBIT growth of 67.6 percent.

Strong growth in both surgical instruments and tables

Sales in Surgical Instruments totalled MSEK 139.6 (98.8) positively affected by the acquisition of Surgical Holdings but negatively impacted by currency headwinds and tariffs. Comparable figures for the quarter, excluding the effect from acquisitions, are MSEK 113.8 corresponding to organic growth of 15.2% and 22.8% in constant currencies.

We saw a positive development in the supply situation for surgical instruments during the quarter,

which enabled us to improve delivery time and start to reduce the backorder level. However, growth was primarily driven by continued strong underlying demand across brands.

I am encouraged about the positive momentum in the UK where our direct sales approach is opening new opportunities for the Group.

Sales in Surgical Tables amounted to MSEK 39.5 (30.5) corresponding to growth of 29.6% (40.3% in constant currencies) driven by strong global demand for both imagiQ3 Legacy and Medstone. We improved profitability – delivering EBIT margin of 10.4% (3.0%) despite currency and tariffs.

Looking ahead

I am very pleased with the start to 2026 and our strong growth in both revenue and profitability. We continue to see strong demand for our products while at the same time improving product availability. With a strengthened Group structure and cash position, we are well positioned to continue building the Stille Group through selective acquisitions. We look forward to the rest of 2026 and further evolving the Stille Group.

Torshälla, April 24, 2026

ULRIK BERTHELSEN
President and CEO

Surgical perfection. For life.

Founded in 1841, Stille AB (publ) is one of the world's oldest medtech companies. With a focus on the needs of surgeons and patients, the Group develops, manufactures and distributes medtech products that simplify and improve the healthcare process.

Over 180 years of premium quality

The Stille of today is the result of over 180 years of innovation within health and medical care services. Since its founding by Albert Stille in 1841, the company has manufactured and marketed premium-quality surgical instruments that have made new types of surgery possible and facilitated the work of surgeons.

In 1887, Stille also began manufacturing and marketing surgical tables, and the company is now a market leader in the segment of surgical tables that are used together with C-arms during minimally invasive vascular procedures.

Surgical perfection and product leadership


Stille's vision is to provide products and solutions that enable perfect surgical procedures: Surgical perfection. For life. Product leadership – achieved, for example, through solid product development in close partnership with leading surgeons – is therefore central to the company's operations.

Brands associated with the highest quality

Surgeons across the world know Stille's brands thanks to the unique quality of their products. Backed by a strong brand profile, the company has a unique position in the market and good opportunities to further develop its offering and increase its market presence in the segments that are profitable for both the company and its customers.

Strong distribution channels and global market presence

Stille currently has offices in Sweden, Switzerland, Germany, the UK, the US and the United Arab Emirates. Through these offices, and together with the Group's robust sales channels, the company's market presence reaches across large parts of the globe. It is through these partners that the company achieves its market expansion.



Our business units

No matter the product portfolio, product leadership and innovation have been part of Stille's business focus since 1841. Today, the operations are divided into two business units: Surgical Tables and Surgical Instruments.

Surgical Instruments

Precision, durability and feel

Precision, durability and feel are characteristic qualities of all Stille's instruments. This has made Stille's premium instruments both well known and appreciated among leading surgeons the world over. The portfolio includes everything from ordinary surgical scissors to unique SuperCut scissors, forceps, clamps and retractors to a broad range of micro instruments.

Product development and world-class innovation

Stille was founded as a solution to the shortage of product development and innovation in surgical instruments. Since 1841, the company has pursued technological development that has made new types of surgical procedures possible. Stille revolutionized the market, for example, in 1923 as the first company in the world to manufacture its instruments in stainless steel. In 1982, Stille also invented the SuperCut scissors. In contrast to their predecessors, these scissors had specially designed cutting surfaces – a combination of scissor and knife edges – allowing them to cut with very high precision all the way to the tip. To this very day, STILLE SuperCut is considered by leading surgeons to be the best scissors in the world.

Surgical Tables

Time-saving multidisciplinary surgical tables

Stille's portfolio of surgical tables is used in a number of different surgical disciplines, including cardiovascular surgery, pain management, ERCP and urological procedures. The surgical tables are characterized by their high level of functionality that reduces surgery time and increases the likelihood of a good outcome. This makes them an attractive choice for surgeons and the OR team.

Taking minimally invasive development forward

Product development is the cornerstone of the business unit, which is Stille's vehicle for taking minimally invasive surgery forward. Development of new surgical tables always takes place in close collaboration with leading surgeons and our partners. One example is the imagiQ3 Legacy surgical table that was launched in November 2024.



SEGMENT OVERVIEW

KSEK	JAN-MAR 2026	JAN-MAR 2025	JAN-DEC 2025
SURGICAL INSTRUMENTS			
Revenue	139,558	98,800	428,693
EBIT before non-recurring items	25,867	16,960	71,720
EBIT before non-recurring items, %	18.5	17.2	16.7
SURGICAL TABLES			
Revenue	39,513	30,490	138,936
EBIT before non-recurring items	4,114	927	8,616
EBIT before non-recurring items, %	10.4	3.0	6.2
TOTAL			
Revenue	179,071	129,290	567,629
EBIT before non-recurring items	29,981	17,887	80,336
EBIT before non-recurring items, %	16.7	13.8	14.2
Transaction costs	—	—	-7,096
Non-recurring items	—	—	—
EBIT	29,981	17,887	73,240
EBIT, %	16.7	13.8	12.9
Net financial items	-4,052	2,187	2,139
Profit before tax	25,929	20,075	75,379

Depreciation and amortization are included in operating profit (EBIT).

BRANDS

Surgical Instruments

STILLE instruments have been manufactured since 1841. Today, they are the only instruments forged from round steel by the company itself. This is a manufacturing method that yields exceptional durability and feel.

S&T is the leading brand in the global micro instrument market. Since the beginning, these products have enabled the development of microsurgery and are today considered to be the world's best micro instruments.

FEHLING offers a broad range of premium products to surgeons, with a focus on demanding specialties such as open and minimally invasive cardiac, thoracic, neuro and spine surgery.

SURGICAL HOLDINGS specializes in the development, distribution and repair of high-quality surgical instruments. Their offering encompasses instruments for general surgery and orthopedics as well as specialized repair services for surgical instruments, rigid endoscopes and orthopedic power tools.

Surgical Tables

imagiQ is the leading brand in the fluoroscopic surgery market. The surgical table is characterized by its unique radiolucency and functionality that reduce both surgery time and radiation exposure.

In 2024, the third generation, imagiQ3 Legacy, was launched, building on the successful legacy of previous generations combined with imagiQ3 Service Integration, which helps to troubleshoot and diagnose problems remotely.

Medstone supplements the product portfolio by being a cost-efficient table for simpler procedures, for example, in pain management and ERCP, where good radiolucency is necessary.



Financial summary

January–March

Net sales

Net sales for the quarter totaled MSEK 179.1 (129.3), positively impacted by acquisition effects of MSEK 25.8 (Surgical Holdings) and negatively by currency translation effects of MSEK –10.8. Comparable figures excluding acquisition effects amounted to sales of MSEK 153.3 (129.3) for the quarter, negatively impacted by currency effects of MSEK –10.8.

Instrument sales for the quarter totaled MSEK 139.6 (98.8). Excluding acquisition effects, sales totaled MSEK 113.8 (98.8). The Surgical Tables business unit's sales for the quarter totaled MSEK 39.5 (30.5). The instrument sales in the quarter were more balanced to demand than in the previous year. Table sales saw another strong quarter, mainly driven by ImagiQ3.

Earnings

Gross profit for the quarter amounted to MSEK 87.9 (66.0), corresponding to a gross profit margin of 49.1 percent (51.1). Acquisition effects amounted to MSEK +11.3. Excluding the acquisition, the gross profit margin was 50.0 percent. Gross profit for the quarter, for both Surgical Instruments and Surgical Tables, was negatively impacted by exchange-rate fluctuations.

EBIT before non-recurring items for the quarter amounted to MSEK 30.0 (17.9), negatively impacted by currency translation effects of MSEK –0.8. No non-recurring items are included in the period or in the comparison period. Consolidated net financial items for the quarter amounted to MSEK –4.1 (2.2), mostly driven by revaluation effects attributable to exchange-rate fluctuations.

Profit before tax for the quarter amounted to MSEK 25.9 (20.1). Profit after tax for the quarter amounted to MSEK 20.9 (14.6). Earnings per share amounted to SEK 2.33 (1.63).

Tax

Tax expense for the quarter totaled MSEK –5.0 (–5.4). As of March 31, 2026, the Group had an accumulated loss carryforward of MSEK 0.9, of which MSEK 0 was directly attributable to the Parent Company.

Cash flow

Consolidated cash flow from operating activities for the quarter amounted to MSEK 27.9 (14.1). Consolidated cash and cash equivalents at the end of the period totaled MSEK 138.2 (148.6).

Financial position

The consolidated equity/assets ratio for the quarter was 67.6 percent (72.6). Consolidated equity at the end of the period totaled MSEK 743.0 (672.4). The Group has a bank overdraft facility of MSEK 50.0 (15.0), of which MSEK 0.0 (0.0) had been utilized as of March 31.

Investments

Net investments in tangible and intangible assets for the quarter totaled MSEK 5.5 (4.4). MSEK 1.3 (1.3) in development costs for new products has been capitalized. Of capitalized development costs, MSEK 0.2 (0.3) pertained to capitalized personnel expenses and MSEK 1.1 (1.0) to capitalized external development costs. Of investments in intangible assets MSEK 1.3 (2.4) relates to MDR readiness.

Employees

The average number of full-time employees (FTEs) in the Group for the quarter was 219 (160). 217 (162) FTEs were employed in the Group on March 31. The increase is primarily attributable to the acquisition of Surgical Holdings.

Parent Company

Net sales in the Parent Company for the quarter totaled MSEK 53.9 (48.7). Profit after tax for the quarter amounted to MSEK 6.8 (9.1). The balance sheet total was MSEK 832.4 (764.8), of which MSEK 582.1 (567.4) comprised equity.

Disclosures on financial commitments

The estimated earnouts in conjunction with the acquisition of S&T AG have been discounted. The appraisal of financial assets and liabilities does not indicate any material difference between carrying amount and fair value.

Related-party transactions

Stille's related parties and transactions with related parties are described in Note 10 of the Annual Report. No transactions between Stille and related parties that had a material impact on the company's position and earnings were conducted during the quarter.

Risks and uncertainties

The Group's and the Parent Company's material estimates and assessments, risks and risk management are described in Note 4 of the Annual Report. Uncertainties concerning the performance of the global economy, and thereby the economic conditions for Stille's end customers, could impact future sales volumes.

Auditor's review

This report has not been reviewed by Stille's auditors.

SHARE AND OWNERSHIP DATA

MARCH 31, 2026

MSEK **1,968**

MARKET CAP

STIL

OMXSPI

11.7% | **-2.2%**

SHARE PRICE DEVELOPMENT
(JAN 1–MAR 31)

8,985,447

SHARES

SEK **219**

SHARE PRICE

2,844

SHAREHOLDERS

SEK **146–219**

LOW/HIGH
(JAN 1–MAR 31)

LARGEST SHAREHOLDERS

	NUMBER	OWNERSHIP SHARE
Linc AB	2,056,075	22.9%
Impilo AB	2,056,075	22.9%
Lannebo Kapitalförvaltning	693,169	7.7%
SEB Funds	501,046	5.6%
Nordnet Pensionsförsäkring	467,818	5.2%
ShapeQ GmbH	418,884	4.7%
Avanza Pension	413,128	4.6%
Ramhill AB	372,209	4.1%
Aktia Asset Management	360,353	4.0%
Fondita Fund Management	180,000	2.0%
Total	7,518,757	83.7%

Share data provided by Modular Finance AB.

Stille's share is listed on the Nasdaq OMX First North Growth Market under the ticker "STIL", ISIN code SE0000998650.

Eminova Fondkommission AB is the Certified Adviser, +46 (0)8 684 211 10, adviser@eminova.se.

Condensed income statement and statement of comprehensive income

GROUP

KSEK	JAN-MAR 2026	JAN-MAR 2025	JAN-DEC 2025
Net sales	179,071	129,290	567,629
Cost of goods sold	-91,204	-63,272	-279,658
Gross profit	87,867	66,018	287,971
Other operating income	1,657	1,935	5,654
Selling expenses	-43,672	-35,593	-151,572
Administrative expenses	-15,205	-12,883	-56,608
Transaction costs	—	—	-7,096
Other operating expenses	-667	-1,589	-5,108
EBIT	29,981	17,887	73,241
Financial income	810	6,965	6,339
Financial expenses	-4,863	-4,777	-4,200
Profit before tax	25,929	20,075	75,380
Income tax	-5,014	-5,452	-19,680
Net profit for the period	20,915	14,623	55,700
Other comprehensive income			
Items that may be reclassified to profit or loss:			
– translation differences in foreign operations	13,346	-41,583	-46,393
COMPREHENSIVE INCOME FOR THE PERIOD	34,261	-26,960	9,307
Earnings per share	2.33	1.63	6.20

Condensed balance sheet

GROUP

KSEK	31 MAR 2026	31 MAR 2025	31 DEC 2025
ASSETS			
Non-current assets			
Intangible assets	553,811	476,886	548,172
Tangible assets	96,051	67,013	92,600
Other financial assets	335		287
Deferred tax assets	6,096	11,482	5,568
Total non-current assets	656,293	555,381	646,627
Current assets			
Inventory	186,224	139,425	182,055
Accounts receivable	97,463	64,856	87,972
Current receivables	20,533	19,414	18,935
Cash and cash equivalents	138,218	148,611	118,660
Total current assets	442,438	372,305	407,622
ASSETS	1,098,731	927,687	1,054,249
EQUITY AND LIABILITIES			
Equity attributable to Parent Company shareholders	742,973	672,445	708,712
Non-current liabilities	230,120	145,038	229,720
Current liabilities	125,638	110,203	115,818
EQUITY AND LIABILITIES	1,098,731	927,687	1,054,249

Condensed statement of changes in equity

GROUP

KSEK	31 MAR 2026	31 MAR 2025	31 DEC 2025
Opening balance	708,712	699,405	699,405
Ongoing new share issue, after tax	—	—	—
Dividend to shareholders	—	—	—
Registered share capital	—	—	—
Provision for share premium reserve	—	—	—
Change in carrying amount of assets	—	—	—
Comprehensive income for the period	34,261	-26,960	9,307
CLOSING BALANCE	742,973	672,445	708,712

Condensed cash flow statement

GROUP

KSEK	JAN-MAR 2026	JAN-MAR 2025	JAN-DEC 2025
OPERATING ACTIVITIES			
<i>Before change in working capital</i>			
EBIT	29,981	17,885	73,241
Adjustment for non-cash items, etc.	7,289	4,079	32,383
Tax paid	-5,167	-7,462	-19,698
Cash flow from operating activities before change in working capital	32,103	14,502	85,926
Change in inventory	-2,297	-564	-28,785
Change in operating receivables	-9,991	20,662	3,391
Change in operating liabilities	8,135	-20,478	-24,477
Total change in working capital	-4,154	-379	-49,871
Cash flow from operating activities	27,949	14,123	36,055
INVESTING ACTIVITIES			
Acquisition of intangible assets	-3,057	-4,019	-14,191
Acquisition/divestment of tangible assets	-2,429	-424	-6,271
Other external assets	—	—	—
Acquisition of operations	—	—	-83,839
Cash flow from investing activities	-5,486	-4,443	-104,301
FINANCING ACTIVITIES			
Dividend to shareholders	—	—	—
Repayment of debts	-5,438	-2,086	-23,056
New share issue, net	0	—	—
Loans raised	0	-9,145	59,218
Cash flow from financing activities	-5,438	-11,231	36,162
CASH FLOW FOR THE PERIOD	17,025	-1,552	-32,084
Cash and cash equivalents at start of period	118,660	158,485	158,485
Translation difference	2,533	-8,323	-7,741
Cash and cash equivalents at end of period	138,218	148,611	118,660

Key performance indicators

GROUP

KSEK	JAN-MAR 2026	JAN-MAR 2025	JAN-DEC 2025
Key performance indicators for profit or loss			
Net sales	179,071	129,290	567,629
Net sales growth, %	38.5	-7.4	-0.4
Gross profit	87,867	66,018	287,971
Gross profit ¹ , %	49.1	51.1	50.7
Depreciation and amortization	-8,508	-7,299	-33,460
EBITDA before non-recurring items²	38,490	25,187	113,797
EBITDA before non-recurring items ² , %	21.5	19.5	20.0
EBITDA²	38,490	25,187	106,701
EBITDA ² , %	21.5	19.5	18.8
EBIT before non-recurring items³	29,981	17,887	80,336
EBIT before non-recurring items ⁴ , %	16.7	13.8	14.2
EBIT³	29,981	17,887	73,241
EBIT ⁴ , %	16.7	13.8	12.9
Net profit for the period	20,915	14,623	55,700
Earnings per share ⁵ , SEK	2.33	1.63	6.20
Comprehensive income after tax	34,261	-26,960	9,307
Key performance indicators for balance sheet			
Net debt	-16,508	-114,999	-16,310
Net debt/EBITDA	-0.1	-0.8	-0.1
Equity/assets ratio ⁶ , %	67.6	72.6	67.2
Equity	742,973	672,445	708,712
Equity per share ⁷ , SEK	82.69	74.84	78.87
Return on equity ⁸ , SEK	4.7	4.4	3.4
Key performance indicators for cash flow statement			
Cash flow from operating activities	27,949	14,123	36,055
Other key performance indicators			
Average number of shares	8,985,447	8,985,447	8,985,447
Number of employees ⁹	219	160	182

Definitions

- Gross profit as a percentage of sales.
- Operating profit (EBITDA) before depreciation and amortization.
- Operating profit (EBIT) comprises profit before financial items and tax.
- The operating margin (EBIT, %) has been calculated as operating profit (EBIT) expressed as a percentage of net sales for the period.
- Net profit for the period (profit after tax) in relation to the average number of shares outstanding.
- The equity/assets ratio has been calculated as equity as a percentage of the total assets in the balance sheet.
- Equity in relation to the average number of shares outstanding at the end of the period.
- Return on equity comprises net profit/loss for the period (profit/loss after tax) as a percentage of weighted equity.
- Number of employees comprises the average number of employees.

Condensed income statement

PARENT COMPANY

KSEK	JAN-MAR 2026	JAN-MAR 2025	JAN-DEC 2025
Net sales	53,901	48,734	184,981
Cost of goods sold	-30,125	-27,814	-109,910
Gross profit	23,777	20,920	75,071
Other operating income	7,782	6,425	23,927
Selling expenses	-6,952	-7,622	-26,339
Administrative expenses	-12,412	-8,780	-39,784
Non-recurring items	—	—	—
Other operating expenses	-258	-651	-4,641
EBIT	11,936	10,292	28,233
Financial income	2,125	-5,564	7,120
Financial expenses	-5,541	6,789	-7,902
Profit after financial items	8,521	11,517	27,451
Appropriations	—	—	-5,948
Profit before tax	8,521	11,517	21,503
Tax on profit for the period	-1,737	-2,372	-4,515
NET PROFIT FOR THE PERIOD	6,784	9,144	16,988

Condensed balance sheet

PARENT COMPANY

KSEK	31 MAR 2026	31 MAR 2025	31 DEC 2025
ASSETS			
Non-current assets			
Intangible assets	41,973	44,253	41,044
Tangible assets	4,702	3,252	4,805
Financial assets	689,171	581,408	685,971
Total non-current assets	735,846	628,914	731,820
Current assets			
Inventory	54,411	51,924	56,292
Accounts receivable	20,185	13,891	14,983
Current receivables	9,686	42,127	6,848
Cash and cash equivalents	12,242	27,930	12,338
Total current assets	96,524	135,873	90,461
ASSETS	832,370	764,787	822,281
EQUITY AND LIABILITIES			
Equity	582,073	567,445	575,289
Untaxed reserves	21,414	15,467	21,415
Non-current liabilities	80,412	98,506	81,612
Current liabilities	148,471	83,370	143,965
EQUITY AND LIABILITIES	832,370	764,787	822,281

Note 1 | Accounting policies

This Interim Report has been prepared in accordance with the International Financial Reporting Standards (IFRS), with the application of IAS 34 Interim Financial Reporting. The consolidated financial statements have been prepared in accordance with IFRS as adopted by the EU as well as recommendation RFR 1 Supplementary Accounting Rules for Corporate Groups. The Parent Company has prepared its accounts in accordance with the Swedish Annual Accounts Act and recommendation RFR 2 Accounting for Legal Entities. The accounting policies and calculation methods remain unchanged compared to the description in the 2025 Annual Report which is available at www.stille.se.

No new or changed accounting standards that came into effect on January 1, 2026 had a material impact on Stille. Stille has decided not to apply in advance new standards, amendments or interpretations that have been published but will not come into effect until the fiscal year beginning on or after January 1, 2027.



Surgical perfection. For life.

Financial calendar

Interim Report Jan–Jun 2026 July 23, 2026
Interim Report Jan–Sep 2026 October 23, 2026

All of the company's financial reports can be found in their entirety on the company's website, www.stille.se.

Stille AB (publ)

Ekbacken 11
SE-644 30, Torshälla
☎ +46 8 588 580 00
✉ info@stille.se
🌐 www.stille.se

More detailed information available from:

Ulrik Berthelsen
President and CEO
☎ +46 70 033 38 25
✉ ulrik.berthelsen@stille.se

This information is information that Stille AB is obligated to make public in accordance with the EU Market Abuse Regulation. The information was submitted for publication on April 24, 2026 at 8:00 a.m. CEST.